AIMS: To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods. METHODS: We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020. A total of six studies involving 4120 patients were included. RESULTS: Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of genital mycotic infections (GMIs) at 26 weeks (p < 0.0001 and p < 0.0001, respectively), 52 weeks (p < 0.00001 and p < 0.0001, respectively), and 104 weeks (p < 0.00001 and p < 0.0001, respectively). Moreover, females had a higher risk of GMIs than males in the 15 mg group at 26 weeks (p = 0.0008), 52 weeks (p < 0.0001), and 104 weeks (p = 0.02). At 104 weeks, 15 mg and 5 mg of ertugliflozin showed beneficial effects on symptomatic hypoglycemia (p < 0.00001 and p = 0.004, respectively) compared with the effects observed in the control group. Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of drug-related adverse events at 26 weeks (p = 0.002 and p = 0.002, respectively); 15 mg of ertugliflozin was associated with a higher risk of discontinuation related to adverse events at 104 weeks (p = 0.03). No significant differences were found in the remaining safety outcomes. CONCLUSION: This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.
AIMS: To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods. METHODS: We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020. A total of six studies involving 4120 patients were included. RESULTS: Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of genital mycotic infections (GMIs) at 26 weeks (p < 0.0001 and p < 0.0001, respectively), 52 weeks (p < 0.00001 and p < 0.0001, respectively), and 104 weeks (p < 0.00001 and p < 0.0001, respectively). Moreover, females had a higher risk of GMIs than males in the 15 mg group at 26 weeks (p = 0.0008), 52 weeks (p < 0.0001), and 104 weeks (p = 0.02). At 104 weeks, 15 mg and 5 mg of ertugliflozin showed beneficial effects on symptomatic hypoglycemia (p < 0.00001 and p = 0.004, respectively) compared with the effects observed in the control group. Compared with the control group, 15 mg and 5 mg of ertugliflozin were associated with higher risks of drug-related adverse events at 26 weeks (p = 0.002 and p = 0.002, respectively); 15 mg of ertugliflozin was associated with a higher risk of discontinuation related to adverse events at 104 weeks (p = 0.03). No significant differences were found in the remaining safety outcomes. CONCLUSION: This meta-analysis of randomized controlled trials indicates that ertugliflozin is tolerated by T2DM, but the risk of GMIs is noteworthy, especially among females in the high-dose group.
Authors: Jennifer R Donnan; Catherine A Grandy; Eugene Chibrikov; Carlo Marra PharmD; Kris Aubrey-Bassler; Karissa Johnston; Michelle Swab; Jenna Hache; Daniel Curnew; Hai Nguyen; John-Michael Gamble Journal: CMAJ Open Date: 2018-12-10
Authors: Jie Liu; Lisa Tarasenko; Steven G Terra; Susan Huyck; Larry Wu; Annpey Pong; Roberto A Calle; Silvina Gallo; Amanda Darekar; James P Mancuso Journal: Diab Vasc Dis Res Date: 2019-05-13 Impact factor: 3.291
Authors: Wendy L Bennett; Nisa M Maruthur; Sonal Singh; Jodi B Segal; Lisa M Wilson; Ranee Chatterjee; Spyridon S Marinopoulos; Milo A Puhan; Padmini Ranasinghe; Lauren Block; Wanda K Nicholson; Susan Hutfless; Eric B Bass; Shari Bolen Journal: Ann Intern Med Date: 2011-03-14 Impact factor: 25.391
Authors: Samuel Dagogo-Jack; Jie Liu; Roy Eldor; Guillermo Amorin; Jeremy Johnson; Darcy Hille; Yuqin Liao; Susan Huyck; Gregory Golm; Steven G Terra; James P Mancuso; Samuel S Engel; Brett Lauring Journal: Diabetes Obes Metab Date: 2017-10-23 Impact factor: 6.577
Authors: Priscilla Hollander; Jie Liu; Julie Hill; Jeremy Johnson; Zhi Wei Jiang; Gregory Golm; Susan Huyck; Steven G Terra; James P Mancuso; Samuel S Engel; Brett Lauring Journal: Diabetes Ther Date: 2017-12-27 Impact factor: 2.945
Authors: Silvina Gallo; Bernard Charbonnel; Allison Goldman; Harry Shi; Susan Huyck; Amanda Darekar; Brett Lauring; Steven G Terra Journal: Diabetes Obes Metab Date: 2019-02-14 Impact factor: 6.577
Authors: Ronnie Aronson; Juan Frias; Allison Goldman; Amanda Darekar; Brett Lauring; Steven G Terra Journal: Diabetes Obes Metab Date: 2018-02-23 Impact factor: 6.577